journal
MENU ▼
Read by QxMD icon Read
search

Clinical Medicine Insights. Oncology

journal
https://www.readbyqxmd.com/read/30093800/early-clinical-outcomes-patterns-of-failure-and-acute-haematologic-toxicity-of-image-guided-volumetric-modulated-arc-therapy-ig-vmat-in-the-definitive-treatment-of-locally-advanced-carcinoma-cervix
#1
Irfan Ahmad, Kundan Singh Chufal, Irfan Bashir, Chandi Prasad Bhatt, Ram Bajpai, Lalit Sharma, Sandeep Rathour
Purpose: To evaluate clinical outcomes and failure patterns in patients with locally advanced cervical cancer (LACC) treated definitively using image-guided volumetric-modulated arc therapy (IG-VMAT). Methods and materials: This retrospective review included 18 consecutively treated patients with LACC. Treatment consisted of IG-VMAT and concurrent chemotherapy followed by intracavitary radiotherapy. The primary end points were overall survival (OS) and disease-free survival (DFS)...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/30083066/survival-study-of-triple-negative-and-non-triple-negative-breast-cancer-in-a-brazilian-cohort
#2
Homero Gonçalves, Maximiliano Ribeiro Guerra, Jane Rocha Duarte Cintra, Vívian Assis Fayer, Igor Vilela Brum, Maria Teresa Bustamante Teixeira
Objective: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors. Methods: This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated. Results: Triple-negative breast cancer corresponded to 19...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/30046260/identifying-risk-factors-for-morbidity-and-mortality-in-patients-with-primary-head-and-neck-cancers-in-a-nigerian-population
#3
Adeyi A Adoga, John P Yaro, Joyce G Mugu, Chukwunonso J Mgbachi
Background: The risk factors for head and neck cancers (HNC) vary in different parts of the world. Objectives: To identify the risk factors for HNC and the correlation between these factors and the involved anatomical sites. Methods: We retrieved and analyzed health records of patients that met the inclusion criteria for HNC managed at our facility in a 10-year period using the International Classification of Diseases (ICD) version 10. Results: We studied 122 patients with a male to female ratio of 2...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/30046259/prospective-analysis-of-patients-with-metastatic-breast-cancer-receiving-eribulin-mesylate-as-second-or-more-lines-of-chemotherapy-an-indian-experience
#4
B J Srinivasa, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia, D Tousif, Raghavendra Rao, Amritanshu Ram, Shekar Patil, Radheshyam Naik
Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients with MBC. Methods: In this study, a total of 45 eligible patients with MBC who received eribulin in HCG Cancer Speciality Center from November 2014 to March 2016 were prospectively analyzed...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29977120/a-single-centre-experience-on-the-management-of-adenosarcoma-a-successful-report-of-an-integrated-medical-and-surgical-approach
#5
Margherita Nannini, Giulia Dondi, Donatella Santini, Antonio De Leo, Angelo Paolo Dei Tos, Claudio Zamagni, Maristella Saponara, Lidia Gatto, Concetta Nigro, Paola Bertaccini, Maurizio Zompatori, Pierandrea De Iaco, Myriam Anna Perrone, Maria Abbondanza Pantaleo
Adenosarcomas are the rarest form of uterine sarcomas, and clinical experience with their management is still limited. Here, we reported 7 patients with uterine adenosarcoma referred to our institution, focusing on main pathologic features, their medical history, and long-term follow-up. Among these patients, we provided a detailed description of the medical history of a 49-year-old woman with advanced uterine adenosarcoma with sarcomatous overgrowth who presented a brilliant radiologic and pathologic response after 3 cycles of epirubicin and ifosfamide, ultimately achieving an extraordinary long-term outcome through an integrated surgical and medical approach...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29899672/malignant-peritoneal-mesothelioma-in-the-setting-of-a-ventriculo-peritoneal-shunt-a-novel-clinical-presentation
#6
Monira Haque, Nadia Hameed, Christopher T Perry, Elliot Carter, Wadad S Mneimneh
We report a case of malignant peritoneal mesothelioma (MPM) in a 31-year-old male with history of cerebral palsy, hydrocephalus, and ventriculoperitoneal shunt (VPS) placed since infancy. He presented with fever, abdominal pain and distension. Computed tomography scan revealed a thick-walled rim-enhancing fluid collection, interpreted as pseudocyst. Intraoperatively, diffuse nodular peritoneal thickening with adhesions was demonstrated. The resection specimen consisted of multiple membranous fragments displaying firm nodules...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29887734/bevacizumab-eligibility-in-patients-with-metastatic-and-recurrent-cervical-cancer-a-retrospective-review
#7
REVIEW
William Paul Skelton, Jacqueline Castagno, Joel Cardenas-Goicoechea, Karen Daily, Anamaria Yeung, Merry Jennifer Markham
Objective: Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurrent CC patients at our institution who would have been eligible to receive bevacizumab. Methods: A retrospective study was conducted to identify metastatic/recurrent CC patients treated at UFHealth between 2006 and 2016...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29887733/the-role-of-osimertinib-in-treatment-na%C3%A3-ve-epidermal-growth-factor-receptor-mutated-stage-iiib-or-iv-non-small-cell-lung-cancer-patients
#8
Dipesh Uprety, Amir Bista, Yazhini Vallatharasu, Lubina Arjyal
No abstract text is available yet for this article.
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29887732/precision-medicine-in-head-and-neck-cancer-myth-or-reality
#9
Eoghan Malone, Lillian L Siu
Standard treatment in head and neck squamous cell carcinoma (HNSCC) is limited currently with decisions being made primarily based on tumor location, histology, and stage. The role of the human papillomavirus in risk stratification is actively under clinical trial evaluations. The molecular complexity and intratumoral heterogeneity of the disease are not actively integrated into management decisions of HNSCC, despite a growing body of knowledge in these areas. The advent of the genomic era has delivered vast amounts of information regarding different cancer subtypes and is providing new therapeutic targets, which can potentially be elucidated using next-generation sequencing and other modern technologies...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29780264/methylation-and-gene-expression-of-bcat1-and-ikzf1-in-colorectal-cancer-tissues
#10
Maher Jedi, Graeme P Young, Susanne K Pedersen, Erin L Symonds
The genes BCAT1 and IKZF1 are hypermethylated in colorectal cancer (CRC), but little is known about how this relates to gene expression. This study assessed the relationship between methylation and gene expression of BCAT1 and IKZF1 in CRC and adjacent non-neoplastic tissues. The tissues were obtained at surgery from 36 patients diagnosed with different stages of CRC (stage I n = 8, stage II n = 13, stage III n = 10, stage IV n = 5). Methylated BCAT1 and IKZF1 were detected in 92% and 72% CRC tissues, respectively, with levels independent of stage ( P  > ...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29720885/successful-second-line-metronomic-temozolomide-in-metastatic-paraganglioma-case-reports-and-review-of-the-literature
#11
Isabel Tena, Garima Gupta, Marcos Tajahuerce, Marta Benavent, Manuel Cifrián, Alejandro Falcon, María Fonfria, Maribel Del Olmo, Rosa Reboll, Antonio Conde, Francisca Moreno, Julia Balaguer, Adela Cañete, Rosana Palasí, Pilar Bello, Alfredo Marco, José Luis Ponce, Juan Francisco Merino, Antonio Llombart, Alfredo Sanchez, Karel Pacak
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B ( SDHB ) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. We report 2 patients with SDHB -related mPGL who received a regimen consisting of MS temozolomide (TMZ) and high-dose lanreotide after progression on both CVD chemotherapy and high-dose lanreotide...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29511362/development-of-molecularly-targeted-agents-and-immunotherapies-in-glioblastoma-a-personalized-approach
#12
REVIEW
Niamh Coleman, Malaka Ameratunga, Juanita Lopez
Over the past decade, precision cancer medicine has driven major advances in the management of advanced solid tumours with the identification and targeting of putative driver aberrations transforming the clinical outcomes across multiple cancer types. Despite pivotal advances in the characterization of genomic landscape of glioblastoma, targeted agents have shown minimal efficacy in clinical trials to date, and patient survival remains poor. Immunotherapy strategies similarly have had limited success. Multiple deficiencies still exist in our knowledge of this complex disease, and further research is urgently required to overcome these critical issues...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29434481/hodgkin-lymphoma-differences-in-treatment-between-europe-and-the-united-states-north-america-evolving-trends-in-protocol-therapy
#13
REVIEW
Thomas J FitzGerald, Maryann Bishop-Jodoin
With continued progress and success in clinical care, the management of patients with Hodgkin lymphoma (HL) has undergone continuous revision to improve patient care outcomes and limit acute and late treatment effects on normal tissue imposed by therapy. Hodgkin lymphoma is a disease that affects children, adolescents, and adults. Clinical management strategies are influenced by the patient's age at diagnosis, tumor burden, response to induction therapy, and potential expectation of treatment impact on normal tissue...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29242703/clinical-characteristics-of-patients-with-renal-cell-carcinoma-and-metastasis-to-the-thyroid-gland
#14
Gregory Jackson, Nora Fino, Rhonda L Bitting
Introduction: Renal cell carcinoma (RCC) is the most common malignancy to metastasize to the thyroid gland. The aims of this study are as follows: (1) to analyze the clinical characteristics of patients with thyroid involvement of RCC and (2) in patients with RCC thyroid metastasis, to determine whether RCC metastasis to glandular organs only portends a better prognosis compared with other patterns of RCC metastasis. Methods: Patients from Wake Forest Baptist Medical Center (WFBMC) diagnosed with thyroid metastasis from RCC were identified and medical records retrospectively examined...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29151782/salvage-low-dose-rate-brachytherapy-for-recurrent-prostate-cancer-after-external-beam-radiotherapy-results-from-a-single-institution-with-focus-on-toxicity-and-functional-outcomes
#15
F Barbera, L Triggiani, M Buglione, P Ghirardelli, P Vitali, B Caraffini, P Borghetti, D Greco, L Bardoscia, N Pasinetti, L Costa, M Maddalo, B Ghedi, B La Face, S M Magrini
Background/aim: Low dose rate brachytherapy has been used as salvage therapy for locally recurrent prostate cancer (PC) after primary external beam radiation therapy (EBRT), along with surgery and cryotherapy. All these techniques, in particular, when applied to the whole gland, involve a relatively high risk of toxicity and may worsen the patient's quality of life. Our aim is to evaluate the results of whole-gland salvage brachytherapy (SBT) after primary EBRT in terms of toxicity, functional outcomes, and efficacy...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29118587/consequences-of-different-corticosteroids-on-serum-potassium-and-prostate-specific-antigen-in-patients-receiving-abiraterone-for-castration-resistant-prostate-cancer-a-retrospective-observational-study
#16
Masaomi Tatsuzawa, Ryuichi Ogawa, Naoki Kinjo, Soan Kim, Fumitaka Shimizu, Yoshiro Sakamoto, Kazuyo Shimojima, Hirotoshi Echizen, Akihisa Miyazaki
Background: Abiraterone acetate is an androgen synthesis inhibitor approved for the treatment of castration-resistant prostate cancer (CRPC). Although co-administration of either prednisone or prednisolone at 10 mg/d has been recommended to reduce the risk of abiraterone-induced hyperaldosteronism (notably hypokalemia) and to give adjunctive pain relief effects, whether these glucocorticoids can be substituted by dexamethasone remains unknown. Methods: We performed a retrospective review of medical records of patients who were given abiraterone for the treatment of CRPC with either prednisolone (ABI/PSL) 10 mg/d or dexamethasone (ABI/DEX) 0...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29051709/effect-of-androgen-deprivation-therapy-on-bone-mineral-density-in-a-prostate-cancer-cohort-in-new-zealand-a-pilot-study
#17
Alice Wang, Nishi Karunasinghe, Lindsay Plank, Shuotun Zhu, Sue Osborne, Karen Bishop, Charis Brown, Tiffany Schwass, Jonathan Masters, Michael Holmes, Roger Huang, Christine Keven, Lynnette Ferguson, Ross Lawrenson
INTRODUCTION: Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT. METHODS: Bone mineral density of the total body, lumbar spine, femoral neck, ultradistal forearm, and one-third distal radius was measured in 88 patients with PCa without bone metastases at baseline and at 6 months...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/28989291/frontline-therapy-for-classical-hodgkin-lymphoma-by-stage-and-prognostic-factors
#18
REVIEW
Pamela B Allen, Leo I Gordon
Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined through prognostic models and positron emission tomography-computed tomography (PET-CT)-directed therapy. Stratification by prognostic models defines groups of patients with favorable characteristics who may be treated with less intensive therapy upfront, including fewer cycles of chemotherapy, lower doses of radiation, or omission of radiation altogether...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/28894395/factors-affecting-adjuvant-therapy-in-stage-iii-pancreatic-cancer-analysis-of-the-national-cancer-database
#19
Mridula Krishnan, Aabra Ahmed, Ryan W Walters, Peter T Silberstein
BACKGROUND: Adjuvant therapy after curative resection is associated with survival benefit in stage III pancreatic cancer. We analyzed the factors affecting the outcome of adjuvant therapy in stage III pancreatic cancer and compared overall survival with different modalities of adjuvant treatment. METHODS: This is a retrospective study of patients with stage III pancreatic cancer listed in the National Cancer Database (NCDB) who were diagnosed between 2004 and 2012...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/28811744/cytogenetic-profile-and-flt3-gene-mutations-of-childhood-acute-lymphoblastic-leukemia
#20
Nawaf Alkhayat, Yasser Elborai, Omer Al Sharif, Mohammad Al Shahrani, Omar Alsuhaibani, Mohammed Awad, Hatem Elghezal, Inesse Ben-Abdallah Bouhajar, Mona Alfaraj, Eman Al Mussaed, Fahad Alabbas, Ghaleb Elyamany
BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent genetic aberrations. The identification of those abnormalities is clinically important because they are considered significant risk-stratifying markers. AIMS: There are insufficient data of cytogenetic profiles in Saudi Arabian patients with childhood ALL leukemia. We have examined a cohort of 110 cases of ALL to determine the cytogenetic profiles and prevalence of FLT3 mutations and analysis of the more frequently observed abnormalities and its correlations to other biologic factors and patient outcomes and to compare our results with previously published results...
2017: Clinical Medicine Insights. Oncology
journal
journal
42907
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"